European Journal of Cancer
Volume 46, Issue 13 , Pages 2357-2368 , September 2010

The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene

Received 23 May 2009 ,Revised 29 March 2010 ,Accepted 6 April 2010.

References 

  1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566[Epub 2007 July 11]
  2. Mossé YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455:
  3. Janoueix-Lerosey I, Lequin D, Brugières L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008;455(7215):967–970
  4. George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008;455(7215):975–978
  5. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature. 2008;455(7215):971–974
  6. Cools J, Wlodarska I, Somers R, et al. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumour. Genes Chromosomes Cancer. 2002;34(4):354–362
  7. Webb TR, Slavish J, George RE, et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther. 2009;9(3):331–356
  8. Jazii FR, Najafi Z, Malekzadeh R, et al. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in oesophageal cancer. World J Gastroenterol. 2006;12(44):7104–7112
  9. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263(5151):1281–1284[Erratum in: Science 1995;267(5196):316–7]
  10. Iwahara T, Fujimoto J, Wen D, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene. 1997;14(4):439–449
  11. Morris SW, Naeve C, Mathew P, et al. ALK, the chromosome 2 gene locus altered by the t (2;5) in non-Hodgkin’s lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene. 1997;14(18):2175–2188
  12. Pulford K, Lamant L, Espinos E, et al. The emerging normal and disease-related roles of anaplastic lymphoma kinase. Cell Mol Life Sci. 2004;61(23):2939–2953[Review]
  13. Allouche M. ALK is a novel dependence receptor: potential implications in development and cancer. Cell Cycle. 2007;6(13):1533–1538[Epub 2007]
  14. Mourali J, Bénard A, Lourenço FC, et al. Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage. Mol Cell Biol. 2006;26(16):6209–6222
  15. Armitage JO, Cavalli, Zucca E, Longo DL. Text Atlas of lymphomas. Revised edition. p. 91. ISBN: 1-84184-180-3 [chapter 9].
  16. Stein H, Foss HD, Dürkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000;96(12):3681–3695[Review]
  17. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263(5151):1281–1284
  18. Passoni L, Gambacorti-Passerini C. ALK a novel lymphoma-associated tumour antigen for vaccination strategies. Leuk Lymphoma. 2003;44(10):1675–1681
  19. Shiota M, Nakamura S, Ichinohasama R, et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood. 1995;86(5):1954–1960
  20. Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999;93(8):2697–2706
  21. Spix C, Pastore G, Sankila R, et al. Neuroblastoma incidence and survival in European children (1978–1997): report from the automated childhood cancer information system project. Eur J Cancer 2006;42(13):2081–91.
  22. Pizzo PA, Poplack DG, editors. Principles and practice of paediatric oncology. 5th ed.; 2006. p. 933. ISBN 0-7817-5492-5 [chapter 31].
  23. Raabe EH, Laudenslager M, Winter C, et al. Prevalence and functional consequence of PHOX2B mutations in neuroblastoma. Oncogene. 2008;27(4):469–476[Epub 2007 July 16]
  24. Yaël P. Mossé, Marci Laudenslager, Luca Longo, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455(7215):930–5.
  25. Isabelle Janoueix-Lerosey, Delphine Lequin, Laurence Brugières, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;55(7215):967.
  26. Yuyan Chen, Junko Takita, Young Lim Choi, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008;455(7215):971.
  27. Rani E. George, Takaomi Sanda, Megan Hanna, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008;455(7215):975.
  28. Woods WG, Tuchman M, Robison L, et al. A population-based study of the usefulness of screening for neuroblastoma. Lancet. 1996;348(9043):1682–1687
  29. Schilling FH, Spix C, Berthold F, et al. Neuroblastoma screening at one year of age. N Engl J Med. 2002;346(14):1047–1053
  30. Tsubono Y, Hisamichi S. A halt to neuroblastoma screening in Japan. N Engl J Med 2004:350(19):2010–1.
  31. Eng C. Cancer: a ringleader identified. Nature. 2008;455(7215):883–884
  32. Griffin CA, Hawkins AL, Dvorak C, et al. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumours. Cancer Res. 1999;59(12):2776–2780
  33. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–2139[Epub 2004 April 29]
  34. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–1500[Epub 2004 April 29]
  35. Mano H. Non-solid oncogenes in solid tumours: EML4–ALK fusion genes in lung cancer. Cancer Sci. 2008;99(12):2349–2355[Epub 2008 November 20, Review].
  36. Inamura K, Takeuchi K, Togashi Y, et al. EML4–ALK fusion is linked to histological characteristics in a subset of lung cancers. Thorac Oncol. 2008;3(1):13–17
  37. Wong DW, Leung EL, So KK, et al. The EML4–ALK fusion gene is involved in various histologic types of lung cancers from non-smokers with wild-type EGFR and KRAS. Cancer 2009.
  38. Martelli MP, Sozzi G, Hernandez L, et al. EML4–ALK rearrangement in non-small cell lung cancer and non-tumour lung tissues. Am J Pathol. 2009;174(2):661–670[Epub 2009 January 15]
  39. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4–ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14(4275):
  40. Wong DW, Leung EL, So KK, et al. The EML4–ALK fusion gene is involved in various histologic types of lung cancer from non-smokers with wild-type EGFR and KRAS. Cancer. 2009;1723–1733
  41. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signalling identifies oncogenic kinases in lung cancer. Cell. 2007;131:1190–1203
  42. Inamura K, Takeuchi K, Togashi Y, et al. Mod Pathol. 2009;22:508–515
  43. Inamura K, Takeuchi K, Togashi Y, et al. EML4–ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008;3:13–17
  44. Horn L, Pao W. EML4–ALK: honing in on a new target in non-small cell lung cancer. JCO. 2009;27:
  45. Passoni L, Gambacorti-Passerini C. ALK a novel lymphoma-associated tumor antigen for vaccination strategies. Leuk Lymphoma. 2003;44(10):1675–1681[Review]
  46. Koivunen JP, Mermel C, Murphy C, et al. EML4–ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res. 2008;14(13):4275–4283
  47. Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4–ALK-positive lung cancer. Proc Natl Acad Sci USA. 2008;105(50):19893–19897[Epub 2008 December]
  48. Shi P, Lai R, Lin Q, et al. IGF-IR tyrosine kinase interacts with NPM–ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells. Blood. 2009;114(2):360–370[Epub 2009 May 7]
  49. Lakshmikuttyamma A, Pastural E, Takahashi N, et al. Bcr-Abl induces autocrine IGF-1 signalling. Oncogene 2008;27(27):3831–44 [Epub 2008 February 4].
  50. Sabbatini P, Korenchuk S, Rowand JL, et al. GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther. 2009;8(10):2811–2820
  51. Kwak EL, Cambridge DR, Clark J, et al. J Clin Oncol. 2009;27(Suppl.):15s;[abstr 3509]
  52. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411(6835):355–365Fluorescence and Giemsa staining. Nature. 1973;243:290–293[Review]
  53. Nowell PC, Hungerford DA. A minute chromosome in human granulocytic leukaemia. Science. 1960;132:1497
  54. Rowley JD. A new consistent chromosome abnormality in chronic myelogenous leukaemia identified by quinacrine. Nature. 1973;243:290–293
  55. O’Brien SG, Guilhot F, Larson RA, et al., IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994–1004.
  56. Renneville A, Roumier C, Biggio V, et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia. 2008;22(5):915–931[Epub 2008, Review]
  57. Mitelman F, Johansson B, Mertens F. Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. Nat Genet. 2004;36(4):331–334
  58. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748):644–648
  59. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008;8(7):497–511[Epub 2008 June 19, Review]
  60. Pizzo PA, Poplack DG, editors. Principles and practice of paediatric pathology. 5th ed. p. 207 [chapter 8].
  61. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8(1):11–23[Review]
  62. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353(23):2477–2490[Review]
  63. de Jong, Vasmel WL, De Boer JP, et al. Anaplastic large-cell lymphoma in women with breast implants. JAMA. 2008;300(17):2030–2035
  64. Astrid A, van der Veldt, Sebastiaan A. Kleijn, Prabath W. Nanayakkara. Silicone breast implants and anaplastic lymphoma. JAMA 2009;301(12):1227.

PII: S0959-8049(10)00309-6

doi: 10.1016/j.ejca.2010.04.006

European Journal of Cancer
Volume 46, Issue 13 , Pages 2357-2368 , September 2010

Article Tools

* Image Usage & Resolution